Phytochemicals against anti-diabetic complications: targeting the advanced glycation end product signaling pathway

Arch Pharm Res. 2021 Apr;44(4):378-401. doi: 10.1007/s12272-021-01323-9. Epub 2021 Apr 9.

Abstract

The role of advanced glycation end products (AGEs) is not limited to diabetes and diabetes-related complications. There are multiple modulators, including the receptor for advanced glycation end products, high mobility group box 1, glyoxalase 1, nuclear factor-kappa B, tumor necrosis factor-α, chronic unpredictable stress, reactive oxygen species, and inflammatory cytokines, which interact with AGE signaling and control diabetes, modulating these interacting modulators. The progression of diabetes, as well as related complications, can be controlled and treated. Natural products rich in bioactive constituents can interact with AGEs and their related mediators through various signaling cascades, thereby controlling and preventing the progression of diabetes. This review provides a deeper assessment of the signaling pathway, interactions between phytochemicals and AGEs, and its mediators, to develop a multifold therapeutic approach to prevent and treat diabetes and its related complications.

Keywords: Advanced glycation end products; Coronary artery disease; Diabetes; Nitric oxide; Phytochemicals; Reactive oxygen species; Receptor for advanced end product glycation.

Publication types

  • Review

MeSH terms

  • Animals
  • Diabetes Mellitus / drug therapy*
  • Glycation End Products, Advanced / antagonists & inhibitors*
  • Glycation End Products, Advanced / metabolism
  • Humans
  • Hypoglycemic Agents / adverse effects
  • Hypoglycemic Agents / antagonists & inhibitors*
  • Hypoglycemic Agents / pharmacology
  • Phytochemicals / chemistry
  • Phytochemicals / pharmacology*
  • Signal Transduction / drug effects

Substances

  • Glycation End Products, Advanced
  • Hypoglycemic Agents
  • Phytochemicals